Comparative Pharmacology
Head-to-head clinical analysis: CEFZIL versus KAFOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFZIL versus KAFOCIN.
CEFZIL vs KAFOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
KAFOCIN (cefepime/enmetazobactam) is a combination of a fourth-generation cephalosporin (cefepime) and a β-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits extended-spectrum β-lactamases (ESBLs) and other class A β-lactamases, restoring cefepime's activity against β-lactamase-producing bacteria. Cefepime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
1 g IV every 8 hours.
None Documented
None Documented
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Terminal elimination half-life: 4.5-6.5 hours (increased to 12-18 hours in severe renal impairment; CrCl <30 mL/min).
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Renal: 60-80% unchanged; biliary/fecal: 15-30% as metabolites; total clearance ~120 mL/min.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic